Neurogene Inc
NGNE21.520USD
-0.260-1.19%
交易中 （美東）報價延遲15分鐘
321.28M總市值
虧損本益比TTM
關於 Neurogene Inc 公司
Neurogene Inc. 是一家臨牀階段的生物技術公司。該公司通過其專有的轉基因調控技術“通過結構調節表達衰減”（EXACT），正在構建一個基因藥物產品組合，用於治療罕見的神經系統疾病，這些疾病具有大量未滿足的需求，而傳統基因療法無法滿足這些需求。其臨牀階段項目 NGN-401 利用 EXACT 平臺，該平臺正在開發用於治療雷特綜合徵，這種疾病的患者羣體具有大量未滿足的需求，最終會發展爲嚴重的神經和身體損傷以及過早死亡。NGN-401 正在一項 1/2 期開放標籤、多中心臨牀試驗中對患有雷特綜合徵的女童患者進行評估，該試驗評估了使用一次性腦室 (ICV) 程序輸送兩劑 NGN-401 的安全性、耐受性和有效性。該公司還在開發用於治療 CLN5 巴頓病的 NGN-101。
公司簡介
公司代碼NGNE
公司名稱Neurogene Inc
上市日期Mar 07, 2014
CEODr. Rachel L. McMinn, Ph.D.
員工數量107
證券類型Ordinary Share
年結日Mar 07
公司地址535 W 24Th Street
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編10011
電話18772375020
網址https://www.neurogene.com/
公司代碼NGNE
上市日期Mar 07, 2014
CEODr. Rachel L. McMinn, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
Dr. Rachel L. McMinn, Ph.D.
Dr. Rachel L. McMinn, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Ms. Christine Mikail Cvijic, J.D.
Ms. Christine Mikail Cvijic, J.D.
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Julie Jordan, M.D.
Ms. Julie Jordan, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
名稱
名稱/職務
職務
持股
持股變動
Dr. Stuart Cobb, Ph.D.
Dr. Stuart Cobb, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
403.00
-94.40%
Mr. Rohan Palekar
Mr. Rohan Palekar
Independent Director
Independent Director
--
--
Mr. Robert Keith Woods
Mr. Robert Keith Woods
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Robert A. Baffi
Dr. Robert A. Baffi
Independent Director
Independent Director
--
--
Dr. Cory Freedland
Dr. Cory Freedland
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Samsara BioCapital, LLC
12.04%
Baker Bros. Advisors LP
10.42%
RTW Investments L.P.
9.46%
Redmile Group, LLC
9.17%
Casdin Capital, LLC
9.08%
Other
49.83%
持股股東
持股股東
佔比
Samsara BioCapital, LLC
12.04%
Baker Bros. Advisors LP
10.42%
RTW Investments L.P.
9.46%
Redmile Group, LLC
9.17%
Casdin Capital, LLC
9.08%
Other
49.83%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
39.97%
Hedge Fund
39.66%
Investment Advisor
18.66%
Venture Capital
12.04%
Individual Investor
9.23%
Research Firm
5.10%
Bank and Trust
0.13%
Pension Fund
0.07%
Insurance Company
0.02%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
207
17.81M
124.87%
-2.19M
2025Q1
216
18.11M
126.54%
-1.93M
2024Q4
211
17.68M
118.99%
+934.89K
2024Q3
193
15.29M
117.57%
+50.95K
2024Q2
185
14.71M
113.65%
+656.15K
2024Q1
190
13.87M
122.85%
+4.51M
2023Q4
186
10.89M
99.88%
+9.09M
2023Q3
208
1.31M
59.57%
-490.20K
2023Q2
215
1.27M
59.11%
-309.84K
2023Q1
219
1.22M
57.26%
-516.47K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Samsara BioCapital, LLC
1.72M
12.04%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
1.49M
10.42%
+811.75K
+120.36%
Mar 31, 2025
RTW Investments L.P.
1.35M
9.46%
-1.60K
-0.12%
Mar 31, 2025
Redmile Group, LLC
1.31M
9.17%
-11.70K
-0.89%
Mar 31, 2025
Casdin Capital, LLC
1.30M
9.08%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
1.27M
8.91%
--
--
Mar 31, 2025
McMinn (Rachel L. Ph.D.)
1.25M
8.77%
-71.49K
-5.41%
Apr 16, 2025
BlackRock Institutional Trust Company, N.A.
946.32K
6.64%
+55.48K
+6.23%
Mar 31, 2025
Commodore Capital LP
925.00K
6.49%
+125.00K
+15.63%
Mar 31, 2025
The Vanguard Group, Inc.
617.93K
4.33%
+49.92K
+8.79%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.66%
iShares Neuroscience and Healthcare ETF
0.43%
Franklin Genomic Advancements ETF
0.14%
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.66%
iShares Neuroscience and Healthcare ETF
佔比0.43%
Franklin Genomic Advancements ETF
佔比0.14%
Fidelity Enhanced Small Cap ETF
佔比0.04%
iShares Micro-Cap ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
iShares Biotechnology ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
公告日期
類型
比率
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Dec 14, 2023
Merger
4<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
Sep 22, 2023
Merger
5<1
